

Neuralstem, Inc.  
Form 8-K  
February 16, 2017

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

---

**Form 8-K**

---

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event Reported): February 16, 2017

**Neuralstem, Inc.**  
(Exact Name of Registrant as Specified in Charter)

**Delaware**  
(State or Other Jurisdiction of  
Incorporation)

**001-33672**  
(Commission File Number)

**52-2007292**  
(I.R.S. Employer Identification  
Number)

**20271 Goldenrod Lane, 2nd Floor, Germantown,  
Maryland 20876**

(Address of Principal Executive Offices) (Zip Code)

**301-366-4960**  
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01. Other Events.**

On February 16, 2017, Neuralstem, Inc. (the “Company”) announced the completion of subject enrollment in its Phase 2 clinical trial of NSI-189 for the treatment of major depressive disorder. A copy of the press release is attached to this report as Exhibit 99.01.

**Item 9.01. Financial Statements and Exhibits.**

| <b>Exhibit No.</b> | <b>Description</b> |
|--------------------|--------------------|
|--------------------|--------------------|

|       |                                          |
|-------|------------------------------------------|
| 99.01 | Press Release Dated February 16,<br>2017 |
|-------|------------------------------------------|

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**Neuralstem, Inc.**

Date: February 16, 2017

By: /s/ Richard Daly  
Richard Daly  
Chief Executive Officer

**INDEX OF EXHIBITS**

**Exhibit No.      Description**

|       |                                          |
|-------|------------------------------------------|
| 99.01 | Press Release Dated February 16,<br>2017 |
|-------|------------------------------------------|